Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05306275 · ClinicalTrials.gov registry record · Phase 1

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

A Phase 1 study of Healthy Participants, sponsored by CSL Behring.

Completed
Registry status
Phase 1
Development phase
132
Enrollment target
1
Study location

NCT05306275 is a Phase 1 study of Healthy Participants that has completed, run by CSL Behring. The registered enrollment target is 132 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (103% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05306275, a Phase 1 study of Healthy Participants, has completed, sponsored by CSL Behring.

COMPLETED
Registry status
Phase 1
Development phase
132 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, parallel-group, phase 1, single center study to assess the relative bioavailability of CSL312 administered subcutaneously via a prefilled syringe assembled to an autoinjector compared to a prefilled syringe assembled to a needle safety device in healthy, adult subjects.

Conditions Studied

Interventions

  • DRUG CSL312

Study Locations (1)

California

  • Anaheim Clinical Trials, LLC - Anaheim

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2022-04-04
Est. Completion 2022-09-27
Phase Phase 1

Sponsor

CSL Behring

71 total trials

What the Registry Record Tells You About NCT05306275

The ClinicalTrials.gov registry entry for NCT05306275 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (103% higher). The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which CSL312 is the first listed.

NCT05306275 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05306275 about?

NCT05306275 is a clinical study titled "A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects". This is an open-label, parallel-group, phase 1, single center study to assess the relative bioavailability of CSL312 administered subcutaneously via a prefilled syringe assembled to an autoinjector compared to a prefilled syringe assembled to a needle safety device in healthy, adult subjects.

What is the current status of trial NCT05306275?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2022-04-04. Estimated completion is 2022-09-27.

What conditions does trial NCT05306275 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT05306275?

The interventions under investigation include: CSL312 (DRUG).

Who is sponsoring clinical trial NCT05306275?

This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05306275 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.